PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 28, 2026The Journal of Maternal-Fetal & Neonatal Medicine1 citationsOpen Access

Present status of sFLT1 and PlGF as diagnostic and therapeutic targets for preeclampsia

View Full Paper
MIMegan N. IrbyCHChaur-Dong HsuVWVeronica Winget

Key Points

  • The study examines the role of sFLT1 and PlGF in preeclampsia and their potential as clinical targets.
  • Assessment of sFLT1/PlGF ratio in diagnosing preeclampsia
  • Evaluation of therapeutic strategies targeting sFLT1
  • Analysis of clinical relevance of sFLT1 as a biomarker
  • sFLT1 is identified as a key biomarker in preeclampsia pathophysiology
  • The sFLT1/PlGF ratio improves risk assessment and management strategies
  • Potential therapies targeting sFLT1 may alter the course of the disease

Abstract

sFLT1 is central to the pathophysiology of preeclampsia and has substantial clinical relevance as both a biomarker and a potential therapeutic target. The sFLT1/PlGF ratio is reshaping risk assessment and management of preeclampsia, while sFLT1-directed therapies may offer future disease-modifying treatment options. Further refinement of biomarker-guided use and therapeutic development is needed before broader implementation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Irby et al. (2026) studied this question.

synapsesocial.com/papers/69c771988bbfbc51511e1999https://doi.org/10.1080/14767058.2026.2648178
Ask AI
Helpful
Bookmark
Share
View Full Paper